Publications by authors named "Laura Cif"

Article Synopsis
  • Dyskinetic disorders (-RD) are a set of neurodevelopmental and movement issues caused by gene variants, with dyskinetic crises characterized by sudden, intense abnormal movements that pose treatment challenges.
  • The study utilized a Delphi consensus method with international experts to create a framework on dyskinetic crises, covering definitions, triggers, diagnostic criteria, complications, and management strategies.
  • The consensus defined dyskinetic crises, noted potential triggers like stress and infections, suggested acute management options such as benzodiazepines, and stressed the need for better education for parents and caregivers to facilitate early recognition and intervention.
View Article and Find Full Text PDF

DBS has been shown to be an effective intervention for neurological disorders. However, the intervention is complex and many aspects have not been understood. Various clinical situations have no solution and follow trial and error approaches.

View Article and Find Full Text PDF

Background: The advent of deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson's disease 30 years ago has ushered a global breakthrough of DBS as a universal method for therapy and research in wide areas of neurology and psychiatry. The literature of the last three decades has described numerous concepts and practices of DBS, often branded as novelties or discoveries. However, reading the contemporary publications often elicits a sense of déjà vu in relation to several methods, attributes, and practices of DBS.

View Article and Find Full Text PDF

The functional characterization of different neuronal types has been a longstanding and crucial challenge. With the advent of physical quantum computers, it has become possible to apply quantum machine learning algorithms to translate theoretical research into practical solutions. Previous studies have shown the advantages of quantum algorithms on artificially generated datasets, and initial experiments with small binary classification problems have yielded comparable outcomes to classical algorithms.

View Article and Find Full Text PDF

Background: Status Dystonicus (SD) represents the most severe end of the spectrum of dystonia. We aimed to explore whether reported features of cases of SD have changed over time.

Methods: A systematic review of cases of SD reported from 2017 to 2023 and comparison of features to data extracted from 2 previous literature reviews (epochs 2012-2017 and pre-2012).

View Article and Find Full Text PDF

Background: Cerebral Palsy (CP) represents a frequent cause of disability in childhood. Early in life, genetic disorders may present with motor dysfunction and diagnosed as CP. Establishing the primary, genetic etiology allows more accurate prognosis, genetic counselling, and planning for symptomatic interventions in homogeneous etiological groups.

View Article and Find Full Text PDF

Background: Most reported patients carrying GNAO1 mutations showed a severe phenotype characterized by early-onset epileptic encephalopathy and/or chorea.

Objective: The aim was to characterize the clinical and genetic features of patients with mild GNAO1-related phenotype with prominent movement disorders.

Methods: We included patients diagnosed with GNAO1-related movement disorders of delayed onset (>2 years).

View Article and Find Full Text PDF

To investigate peripheral blood methylation episignatures in -related dystonia (DYT-), the authors undertook genome-wide methylation profiling of ∼2 M CpGs using a next-generation sequencing-based assay and compared the findings with those in controls and patients with -related Kabuki syndrome type 1 (KS1). A total of 1812 significantly differentially methylated CpG positions (false discovery rate < 0.05) were detected in DYT samples compared with controls.

View Article and Find Full Text PDF
Article Synopsis
  • ADCY5-related dyskinesia is an early-onset movement disorder without an established treatment, but there's anecdotal evidence suggesting caffeine may help improve symptoms.
  • A worldwide study involving 30 patients indicated that caffeine was well tolerated, with 87% reporting symptom improvement, including reduced movement disorder frequency and enhanced quality of life.
  • The study concludes that caffeine could be a viable first-line treatment option for patients with ADCY5-related dyskinesia.
View Article and Find Full Text PDF

Deep brain stimulation (DBS) serves as a treatment for neurological and psychiatric disorders, such as Parkinson's disease (PD), essential tremor, dystonia, Tourette Syndrome (GTS), Huntington's disease, and obsessive-compulsive disorder (OCD). There is broad experience with the short-term effects of DBS in individual diseases and their signs/symptoms. However, even in acute treatment and for the same disorder or a given disorder, a prediction of effect is not perfect.

View Article and Find Full Text PDF

Recently, a series of historical reports portrayed the first women neurosurgeons in various countries. One such woman, a pioneer on many levels, remained unrecognized: Judith Balkányi-Lepintre. She was the first woman neurosurgeon in France, the first woman war neurosurgeon for the French Army, and the first woman pediatric neurosurgeon in France.

View Article and Find Full Text PDF
Article Synopsis
  • - CHD8 loss-of-function variants, initially linked to autism, are now linked to a broader range of neurodevelopmental disorders, including dystonia.
  • - Two unrelated patients with childhood-onset progressive dystonia were found to have different CHD8 variants through whole-exome sequencing.
  • - Both patients exhibited similar symptoms and showed clinical improvement after deep brain stimulation, suggesting that CHD8 mutations can lead to dystonia as a primary feature.
View Article and Find Full Text PDF

Aim: To provide insight into outcome and long-term safety and efficacy of deep brain stimulation (DBS), from the perspective of individuals with Lesch-Nyhan disease (LND) and their families.

Method: We used patient-centered outcome measures to assess long-term outcomes of DBS for 14 individuals (mean [SD] age 10y 10mo [5y 6mo], range 5-23y, all males) with LND, after an average duration of 5y 6mo (range 11mo-10y 5mo) after surgery. We compared these results with a comprehensive review of previously published cases.

View Article and Find Full Text PDF

Early-onset torsion dystonia (TOR1A/DYT1) is a devastating hereditary motor disorder whose pathophysiology remains unclear. Studies in transgenic mice suggested abnormal cholinergic transmission in the putamen, but this has not yet been demonstrated in humans. The role of the cerebellum in the pathophysiology of the disease has also been highlighted but the involvement of the intrinsic cerebellar cholinergic system is unknown.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the effectiveness of fosmetpantotenate in improving symptoms and stabilizing disease progression for patients with Pantothenate kinase-associated neurodegeneration (PKAN), a condition with no approved treatments.
  • Conducted over 24 weeks, the randomized, double-blind, placebo-controlled trial included 84 patients aged 6 to 65 with specific genetic mutations, comparing the effects of a 300 mg oral dose of fosmetpantotenate against a placebo.
  • Results showed that fosmetpantotenate was safe; however, it did not demonstrate a significant improvement in patient function as measured by the PKAN-Activities of Daily Living scale.
View Article and Find Full Text PDF
Article Synopsis
  • Heterozygous mutations in the KMT2B gene are linked to early-onset dystonia (DYT28), featuring motor problems that start locally and can spread throughout the body, particularly affecting the face and neck.
  • A study of 53 patients with KMT2B mutations revealed new disease presentations and identified various health issues, such as growth retardation and endocrine disorders, as well as a higher impact on patients with more severe genetic variants.
  • Patients who underwent deep brain stimulation for severe dystonia showed significant improvement in motor function and disability over time, with more than half experiencing over 30% improvement at the one-year mark.
View Article and Find Full Text PDF
Article Synopsis
  • Huntington's disease (HD) is a progressive neurodegenerative disorder that leads to motor, psychiatric, and cognitive decline, and this study investigates the effects of Continuous Electrical Neuromodulation (CEN) on cognitive decline in HD patients.
  • A total of 13 HD patients received neuromodulation treatment from 2008 to 2019, and their cognitive function was assessed using the Mattis Dementia Rating Scale over a 5-year follow-up period.
  • Results showed significant improvement in chorea symptoms post-surgery and a stabilization of cognitive function in the first three years, suggesting that GPi-CEN may help delay cognitive decline in early-stage HD patients.
View Article and Find Full Text PDF

Introduction: Deep brain stimulation (DBS) is a well-established treatment for movement disorders. High magnetic fields could have an impact on distortion. We evaluated 1.

View Article and Find Full Text PDF

Objectives: The majority of people with suspected genetic dystonia remain undiagnosed after maximal investigation, implying that a number of causative genes have not yet been recognized. We aimed to investigate this paucity of diagnoses.

Methods: We undertook weighted burden analysis of whole-exome sequencing (WES) data from 138 individuals with unresolved generalized dystonia of suspected genetic etiology, followed by additional case-finding from international databases, first for the gene implicated by the burden analysis (VPS16), and then for other functionally related genes.

View Article and Find Full Text PDF

: To reveal clinical characteristics of suboptimal responses to deep brain stimulation (DBS) in a multi-country DYT1 dystonia cohort. : In this multi-country multi-center retrospective study, we analyzed the clinical data of DYT1 patients who experienced suboptimal responses to DBS defined as <30% improvement in dystonia scales at the last follow-up compared with baseline. We used a literature-driven historical cohort of 112 DYT1 patients for comparison.

View Article and Find Full Text PDF